Capricor Therapeutics is taking a victory lap for their phase 2 Duchenne muscular dystrophy (DMD) trial. At three years, the San Diego-based company’s cell therapy deramiocel improved patients’ left ventricular ejection fraction and ability to use their upper limbs.
Alaunos Therapeutics is axing an agreement with Precigen, giving up licensing rights to a personalized T-cell platform.
Bruker has formed a new, single division out of the various spatial biology assets it has acquired over the years.
Turnstone Biologics is reducing its head count by 60% and shaking up its C-suite in order to keep the cash flowing to its sole clinical-stage candidate.
The world is absolutely teeming with viruses. The infectious agents are widely considered the most abundant biological entity on Earth. But a full understanding of viruses and the roles they play in our world is limited by our paltry knowledge of their incredible diversity.
Booster Therapeutics has launched with $15 million in seed financing and a mission to take on the current crop of targeted protein degraders.
Gritstone bio may have left no stone unturned when it came to searching for a financial rescue, but the vaccine biotech has decided that all roads now lead to bankruptcy.
The digital diabetes developer Glooko has collected $100 million and a new CEO to help boost the trajectory of its data management platform.
Finnish biotech Orion has spied potential in Aitia’s “digital twin” tech to develop new cancer drugs.
While Windtree Therapeutics has struggled to grow the financial roots needed to survive, a phase 2 win for the biotech’s lead asset will at least give the company encouragement to persevere.
Capricor cell therapy improves cardiac and upper limb function in phase 2 Duchenne muscular dystrophy victory lap
After axing its sole clinical prospect last year, Alaunos cuts ties with Precigen
Bruker spools up spatial biology division from NanoString, Canopy assets
Turnstone lays off 60% of staff, shakes up C-suite to keep cancer cell therapy on track
Deep learning AI model scans ‘dark matter’ of genomic data to find 70,000 never-before-seen RNA viruses
Novo Holdings-backed Booster takes off with protein degraders aimed at neurodegeneration
Gritstone files for bankruptcy in hope of keeping cancer vaccine R&D afloat
Glooko collects $100M, plus a new CEO, to boost its diabetes platform
Weekly Market Review – January 25, 2025
Weekly Market Review – January 18, 2024
